中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (4): 257-262.doi: 10.19401/j.cnki.1007-3639.2021.04.003

• 专家述评 • 上一篇    下一篇

恶性肿瘤植入放射性 125 I粒子出现迁移的研究现状与展望

朱俊军,葛乃建,杨业发   

  1. 海军军医大学第三附属医院东方肝胆微创介入中心,上海 201805
  • 出版日期:2021-04-30 发布日期:2021-04-28
  • 通信作者: 杨业发 E-mail: yangyefa66@163.com
  • 基金资助:
    国家自然科学基金(31971249)。

Current status and prospects of migration of radioactive  125 I seed implanted in malignant tumor 

ZHU Junjun, GE Naijian, YANG Yefa#br#   

  1. Eastern Hepatobiliary Intervention Center, the Third Affiliated Hospital of Naval Medical University, Shanghai 201805, China
  • Published:2021-04-30 Online:2021-04-28
  • Contact: YANG Yefa E-mail: yangyefa66@163.com

摘要: 癌症是严重危害人类健康的疾病之一,其发病数和死亡数仍呈持续增加态势,给全球公共卫生系统带来了沉重的负担。在与肿瘤的长期斗争过程中,人们提出了各种各样的方法。100多年前,刚发现伦琴射线不久,人们就开始探索将放射线用于肿瘤的治疗,由此开创了肿瘤放射治疗学。组织间植入放射性粒子治疗肿瘤作为最早开展的近距离放射治疗技术之一,其益处早已得到公众认可,成为肿瘤治疗谱中重要的一员。在放射性粒子植入治疗的实践中,会出现一些粒子离开初始种植位置而到达其他位置的粒子迁移事件。现就恶性肿瘤组织间插植 125 I粒子、 125 I粒子迁移及其成因、产生的影响、防护等进行综述。

关键词: 恶性肿瘤, 近距离放疗, 放射性 125 I, 粒子迁移

Abstract: Cancer is one of the diseases that seriously harm human health. The cancer-related incidence and deaths are still increasing worldwide, which has brought heavy burden to the global public health system. During the long anticancer history, a variety of methods to treat tumors have been developed. More than 100 years ago, shortly after the discovery of Roentgen rays, people began to treat tumors with radiation, and thus pioneered radiation oncology. As a brachytherapy method, implantation of radioactive seeds acts well, has received public recognition, and becomes an important member of the oncology therapeutic spectrum. In vivo, some seeds can migrate from initial site of implantation to other locations. Permanent interstitial brachytherapy and the incidence, mechanism, influence and prevention of  125 I seed migration were reviewed here.

Key words: Malignant tumor, Brachytherapy, Radioactive , 125 I, Seed migration